Head-to-head evidence
KSI-301 vs RGX-314
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Age-Related Macular Degeneration
Shared mechanism: VEGF-A · full Age-Related Macular Degeneration pipeline
KSI-301
Developed by Kodiak Sciences Inc.
NCT04964089 · Phase 3 · completed
This was a randomized, triple-masked, active-controlled trial with 276 participants receiving KSI-301 and 281 receiving aflibercept. The hard clinical primary endpoint, change in best-corrected visual acuity, met the prespecified non-inferiority criterion: the adjusted difference was -2.1 ETDRS letters (95% CI -3.88 to -0.29; p=0.0083).
RGX-314
Developed by REGENXBIO Inc.
NCT04832724 · Phase 2 · completed
The study enrolled 60 participants into sequential RGX-314 dose and formulation groups without randomization, blinding, or a comparator arm. Its primary endpoint was the surrogate pharmacodynamic measure of RGX-314 protein concentration, and no primary outcome results are available.
Next expected readout: December 2026 · NCT04704921 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: KSI-301's landscape · RGX-314's landscape